KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) Gross Profit (2016 - 2025)

Neogenomics' Gross Profit history spans 16 years, with the latest figure at $83.3 million for Q4 2025.

  • For Q4 2025, Gross Profit rose 7.88% year-over-year to $83.3 million; the TTM value through Dec 2025 reached $314.3 million, up 8.34%, while the annual FY2025 figure was $314.3 million, 8.34% up from the prior year.
  • Gross Profit reached $83.3 million in Q4 2025 per NEO's latest filing, up from $80.4 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $83.3 million in Q4 2025 to a low of $38.2 million in Q1 2022.
  • Average Gross Profit over 5 years is $61.2 million, with a median of $61.1 million recorded in 2023.
  • The largest YoY upside for Gross Profit was 89.21% in 2021 against a maximum downside of 21.23% in 2021.
  • A 5-year view of Gross Profit shows it stood at $45.3 million in 2021, then grew by 25.56% to $56.8 million in 2022, then increased by 18.94% to $67.6 million in 2023, then rose by 14.31% to $77.3 million in 2024, then grew by 7.88% to $83.3 million in 2025.
  • Per Business Quant, the three most recent readings for NEO's Gross Profit are $83.3 million (Q4 2025), $80.4 million (Q3 2025), and $77.3 million (Q2 2025).